Download PDF
Thromb Haemost 2015; 114(04): 657-659
DOI: 10.1160/TH15-06-0518
Invited Editorial Focus
Schattauer GmbH

The SAMe-TT2R2 score and quality of anticoagulation in AF: Can we predict which patient benefits from anticoagulation?

Laurent Fauchier
1   Service de Cardiologie, Pôle Coeur Thorax Vasculaire, Centre Hospitalier Universitaire Trousseau et Faculté de Médecine, Université François Rabelais, Tours, France
,
Daniela Poli
2   Department of Heart and Vessels, Thrombosis Centre, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
,
Brian Olshansky
3   Division of Cardiology, Cardiac Electrophysiology Mercy Hospital – North Iowa, Mason City, Iowa, USA
› Author Affiliations
Further Information

Publication History

Received: 26 June 2015

Accepted: 26 June 2015

Publication Date:
29 November 2017 (online)

Also available at
    Permissions and Reprints

Editorial Focus on: Ruiz-Ortiz et al. Thromb Haemost 2015; 114: 695-701.

 

  • References

  • 1 Lip GYH, Laroche C, Ioachim PM. et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORPAF Pilot registry). Eur Heart J 2014; 35: 3365-3376.
    CrossrefPubMedGoogle Scholar
  • 2 De Caterina R, Husted S, Wallentin L. et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Gallego P, Roldan V, Marín F. et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110: 1189-1198.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Apostolakis S, Sullivan RM, Olshansky B. et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest 2013; 144: 1555-1563.
    CrossrefPubMedGoogle Scholar
  • 5 Ruiz-Ortiz M, Beromeu V, Ángel C. et al. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. Thromb Haemost 2015; 114: 695-701.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Abumuaileq RR-Y, Abu-Assi E, Raposeiras-Roubin S. et al. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with nonvalvular atrial fibrillation on vitamin-K antagonists. Europace 2015; 17: 711-717.
    CrossrefPubMedGoogle Scholar
  • 7 Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis 2000; 9: 283-292.
    CrossrefPubMedGoogle Scholar
  • 8 Wan Y, Heneghan C, Perera R. et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008; 1: 84-91.
    CrossrefPubMedGoogle Scholar
  • 9 Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis 2003; 15: 213-216.
    CrossrefPubMedGoogle Scholar
  • 10 Gallego P, Roldán V, Marin F. et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 2014; 127: 1083-1088.
    CrossrefPubMedGoogle Scholar
  • 11 Lip GYH, Haguenoer K, Saint-Etienne C. et al. Relationship of the SAMe-TT[two.inferior]R[two.inferior] score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest 2014; 146: 719-726.
    CrossrefPubMedGoogle Scholar
  • 12 Poli D, Antonucci E, Testa S. et al. A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med 2014; 9: 443-447.
    CrossrefPubMedGoogle Scholar
  • 13 Dlott JS, George RA, Huang X. et al. National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation 2014; 129: 1407-1414.
    CrossrefPubMedGoogle Scholar
  • 14 Holbrook A, Schulman S, Witt DM. et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e152S-184S.
    CrossrefPubMedGoogle Scholar
  • 15 Rose AJ, Hylek EM, Ozonoff A. et al. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost 2010; 8: 2182-2191.
    CrossrefPubMedGoogle Scholar
  • 16 Authors/Task Force Members. Camm AJ, Lip GYH. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
    CrossrefPubMedGoogle Scholar
  • 17 January CT, Wann LS, Alpert JS. et al. 2014 AHA/ ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: e1-76.
    CrossrefPubMedGoogle Scholar
  • 18 Wallentin L, Yusuf S, Ezekowitz MD. et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-983.
    CrossrefPubMedGoogle Scholar